Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock

被引:233
作者
Kohsaka, S
Menon, V
Lowe, AM
Lange, M
Dzavik, V
Steeper, LA
Hochman, JS
机构
[1] NYU, Sch Med, Cardiovasc Clin Res Ctr, New York, NY 10016 USA
[2] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Univ N Carolina, Dept Cardiol, Chapel Hill, NC USA
[5] New England Res Inst, Watertown, MA USA
[6] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Med, New York, NY USA
[7] Univ Toronto, Div Cardiol, Toronto, ON, Canada
关键词
D O I
10.1001/archinte.165.14.1643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of inflammation in patients with coronary artery disease is emerging. We sought to assess the profile and outcomes of patients with a clinical syndrome of severe systemic inflammation that led to a diagnosis of suspected sepsis in the setting of acute myocardial infarction complicated by cardiogenic shock (CS). Methods: Patients enrolled in the randomized SHOCK (SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK) trial (n=302) were divided into those with clinical signs of severe systemic inflammation (eg, fever [94%] or leukocytosis [72%]) that led to a diagnosis of suspected sepsis (n= 54 [18%]) and those without suspected sepsis (controls; n = 243 [80%]). The patients with suspected sepsis were then further subdivided into those who were considered to be potentially infectious (positive culture result ["culture-positive"]; n=40) and those who were not (negative culture result ["culture-negative"]; n = 14). Results: Severe systemic inflammation was diagnosed 4 and 2 days after the onset of CS in culture-positive and culture-negative patients, respectively. Patients who developed systemic inflammation tended to be younger (P=.05) and to have lower systemic vascular resistance (SVR) near the onset of CS (P=.006). Many culture-positive patients (40%) had undergone coronary artery bypass graft surgery. However, the lower the initial SVR, the higher the risk of developing culture-positive systemic inflammation (P=.01), even after controlling for age and coronary artery bypass graft surgery. A time-dependent model, adjusted for age, showed that culture-positive patients were at significantly higher risk for death than were controls (hazard ratio, 2.22; 95% confidence interval, 1.32-3.76; P=.008). Conclusions: Almost one fifth of patients with acute myocardial infarction complicated by CS showed clinical signs of severe systemic inflammation, and those who were culture-positive for sepsis had twice the risk of death. The observation of lower SVR at the onset of shock in patients who subsequently had culture-positive systemic inflammation suggests that inappropriate vasodilation may play an important role in the pathogenesis and persistence of shock and in the risk of infection.
引用
收藏
页码:1643 / 1650
页数:8
相关论文
共 24 条
[1]   Widespread coronary inflammation in unstable angina [J].
Buffon, A ;
Biasucci, LM ;
Liuzzo, G ;
D'Onofrio, G ;
Crea, F ;
Maseri, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (01) :5-12
[2]   LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock - A prospective randomized study [J].
Cotter, G ;
Kaluski, E ;
Milo, O ;
Blatt, A ;
Salah, A ;
Hendler, A ;
Krakover, R ;
Golick, A ;
Vered, Z .
EUROPEAN HEART JOURNAL, 2003, 24 (14) :1287-1295
[3]   L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock [J].
Cotter, G ;
Kaluski, E ;
Blatt, A ;
Milovanov, O ;
Moshkovitz, Y ;
Zaidenstein, R ;
Salah, A ;
Alon, D ;
Michovitz, Y ;
Metzger, M ;
Vered, Z ;
Golik, A .
CIRCULATION, 2000, 101 (12) :1358-1361
[4]   Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6 [J].
Geppert, A ;
Steiner, A ;
Zorn, G ;
Delle-Karth, G ;
Koreny, M ;
Haumer, M ;
Siostrzonek, P ;
Huber, K ;
Heinz, G .
CRITICAL CARE MEDICINE, 2002, 30 (09) :1987-1994
[5]   Temporal trends in cardiogenic shock complicating acute myocardial infarction [J].
Goldberg, RJ ;
Samad, NA ;
Yarzebski, J ;
Gurwitz, J ;
Bigelow, C ;
Gore, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (15) :1162-1168
[6]   Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial [J].
Granger, CB ;
Mahaffey, KW ;
Weaver, WD ;
Theroux, P ;
Hochman, JS ;
Filloon, TG ;
Rollins, S ;
Todaro, TG ;
Nicolau, JC ;
Ruzyllo, W ;
Armstrong, PW .
CIRCULATION, 2003, 108 (10) :1184-1190
[7]   The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations [J].
Hall, RI ;
Smith, MS ;
Rocker, G .
ANESTHESIA AND ANALGESIA, 1997, 85 (04) :766-782
[8]  
Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5
[9]   Early revascularization in acute myocardial infarction complicated by cardiogenic shock [J].
Hochman, JS ;
Sleeper, LA ;
Webb, JG ;
Sanborn, TA ;
White, HD ;
Talley, JD ;
Buller, CE ;
Jacobs, AK ;
Slater, JN ;
Col, J ;
McKinlay, SM ;
LeJemtel, TH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (09) :625-634
[10]   One-year survival following early revascularization for cardiogenic shock [J].
Hochman, JS ;
Sleeper, LA ;
White, HD ;
Dzavik, V ;
Wong, SC ;
Menon, V ;
Webb, JG ;
Steingart, R ;
Picard, MH ;
Menegus, MA ;
Boland, J ;
Sanborn, T ;
Buller, CE ;
Modur, S ;
Forman, R ;
Desvigne-Nickens, P ;
Jacobs, AK ;
Slater, JN ;
LeJemtel, TH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (02) :190-192